PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease
Abstract AIM: Limitations of conventional phosphate binders have led to the development of novel non-calcium, non-aluminium agents for use in patients with chronic kidney disease (CKD).